Premium
Neutrophil CD64 expression as a longitudinal biomarker for severe disease and acute infection in critically ill patients
Author(s) -
Jong E.,
Lange D. W.,
Beishuizen A.,
Ven P. M.,
Girbes A. R. J.,
Huisman A.
Publication year - 2016
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12545
Subject(s) - cd64 , medicine , sepsis , septic shock , biomarker , prospective cohort study , critically ill , shock (circulatory) , intensive care medicine , biochemistry , chemistry , receptor
Summary Introduction Neutrophilic granulocytes express cluster of differentiation 64 ( CD 64) antigen upon activation. CD 64 can be used as a marker of bacterial infection and sepsis. The goal of this study was to determine whether CD 64 is a useful biomarker for critically ill patients and analyze longitudinal measurements with regard to outcome and sepsis severity. Methods In this prospective observational study, CD 64 analysis was performed daily until discharge from ICU or death. Demographics, clinical, laboratory data, and outcome defined as 28‐day survival were recorded. Patients were included when admitted to the ICU with sepsis, severe sepsis, or septic shock and within 24 h from start of antibiotic treatment. Results Hundred and fifty‐five consecutive patients were enrolled. At baseline, a difference in CD 64 of 2.26 (1.33–4.47) vs . 1.49 (0.89–2.24) ( P = 0.004) was seen between patients with a positive culture and negative culture. CD 64 at day 1 was higher with patients with septic shock when compared with sepsis ( P = 0.012). No difference of CD 64 between survivors and nonsurvivors was seen. Conclusion This study demonstrated that CD 64 discriminates between critically ill patients with culture positive and negative sepsis and correlates with severity of disease. However, CD 64 index is not a good predictor for 28‐day mortality in the critically ill patient.